Eric Crombez - May 1, 2023 Form 3 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role: EVP and Chief Medical Officer
Signature: /s/ Karah Parschauer, attorney-in-fact
Stock symbol: RARE
Transactions as of: May 1, 2023
Transactions value $: $0
Form type: 3
Date filed: 5/2/2023, 06:14 PM
Next filing: Sep 29, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	RARE	Common Stock						25.9K	May 1, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	RARE	Stock Option (Right to Buy)							May 1, 2023	Common Stock	7.5K	$48.11	Direct	F2
holding	RARE	Stock Option (Right to Buy)							May 1, 2023	Common Stock	8K	$67.55	Direct	F3
holding	RARE	Stock Option (Right to Buy)							May 1, 2023	Common Stock	13K	$56.08	Direct	F4
holding	RARE	Stock Option (Right to Buy)							May 1, 2023	Common Stock	4.31K	$142.47	Direct	F5
holding	RARE	Stock Option (Right to Buy)							May 1, 2023	Common Stock	6.34K	$67.37	Direct	F6
holding	RARE	Stock Option (Right to Buy)							May 1, 2023	Common Stock	9.85K	$45.65	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 12,601 Restricted Stock Units ("RSUs") awarded under the Company's 2014 Incentive Plan. The RSUs vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. Of the 12,601 RSUs, 1,115 RSUs were granted on March 1, 2020, 720 RSUs were granted on March 1, 2021, 1,000 RSUs were granted on April 16, 2021, 2,381 RSUs were granted on March 1, 2022 and 7,385 RSUs were granted on March 1, 2023.
F2	1/4th of the shares initially subject to the option vested on November 17, 2018; thereafter, 1/48th of the shares initially subject to the option vested monthly.
F3	1/4th of the shares initially subject to the option vested on March 1, 2020; thereafter, 1/48th of the shares initially subject to the option vested monthly.
F4	1/4th of the shares initially subject to the option vested on March 1, 2021 thereafter, 1/48th of the shares initially subject to the option shall vest monthly.
F5	1/4th of the shares initially subject to the option vested on March 1, 2022 thereafter, 1/48th of the shares initially subject to the option shall vest monthly.
F6	1/4th of the shares initially subject to the option vested on March 1, 2023 thereafter, 1/48th of the shares initially subject to the option shall vest monthly.
F7	1/4th of the shares initially subject to the option will vest on March 1, 2024 thereafter, 1/48th of the shares initially subject to the option shall vest monthly.